Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHP107 (Oral Paclitaxel) in Advanced Solid Cancer
NCT02890511Phase 2Completed
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Aug 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel oral solution in solid tumor and gastric cancer (GC), sponsored by Daehwa Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 4 weeks. Started Aug 2010; status: completed.
02
Drugs
paclitaxel oral solution
03
Conditions
solid tumorgastric cancer (GC)
Beyond the preview
Go deeper on NCT02890511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890511.